Analyst Ratings January 28, 2026

JPMorgan Sticks With Overweight on ASML After Orders Surge, Sees Bigger Upgrades Ahead

Bank points to exceptional Q4 bookings and raises outlook for multi-year up-cycle; valuation remains a consideration

By Ajmal Hussain ASML
JPMorgan Sticks With Overweight on ASML After Orders Surge, Sees Bigger Upgrades Ahead
ASML

JPMorgan reaffirmed an Overweight rating on ASML and set a $1,518 price target, citing a substantial beat in fourth-quarter 2025 orders. The company reported record revenue and robust bookings that suggest stronger results ahead, while select valuation metrics indicate the stock may be rich relative to fair value.

Key Points

  • JPMorgan reaffirmed an Overweight rating on ASML and set a $1,518 price target, driven by exceptional order performance.
  • ASML reported Q4 2025 bookings of c13.2 billion, beating JPMorgan estimates by 88% and consensus by 93.6%, and recorded Q4 net revenue of c9.7 billion.
  • The company provided FY2026 sales guidance centered at a c36.5 billion midpoint, an 11.7% year-over-year increase and 3.5% above consensus; analysts expect larger estimate upgrades in 2027 and 2028.

JPMorgan has held to an Overweight rating for ASML with a price target of $1,518, underscoring the chip-equipment maker's strong order momentum. The firm highlighted fourth-quarter 2025 order intake that materially exceeded expectations and signaled scope for meaningful estimate revisions in subsequent years.

ASML's share price is trading at $1,454.59 - roughly 0.99% below its 52-week high - and carries a price-to-earnings ratio of 53.19, according to InvestingPro data, which the bank notes may place the stock above its Fair Value.

The company reported fourth-quarter 2025 bookings of c13.2 billion, a result that topped JPMorgan's internal projection by 88% and rose 93.6% above consensus forecasts. That level of order intake was cited by the bank as a key driver for its continued positive stance, as it implies stronger demand beyond the current fiscal year.

For fiscal 2026, ASML provided sales guidance in a range described as c34-30 billion. JPMorgan highlighted that the midpoint of that band, c36.5 billion, represents an 11.7% increase year-over-year and sits 3.5% above consensus. While the FY26 outlook itself is constructive, the investment bank emphasized that the exceptional bookings imply FY27 could be materially stronger, prompting expectations for significant upward estimate revisions.

JPMorgan's view frames ASML as being in a multi-year up-cycle, with potential for analyst estimates to be lifted across 2026, 2027, and 2028. The bank anticipates the largest percentage upgrades to occur in 2027 and 2028, where it expects double-digit increases to consensus forecasts.

Separately, ASML reported record net revenue of c9.7 billion for the fourth quarter of 2025. That quarterly revenue figure was 5% higher than the year-ago quarter and represented a 29% rise from the prior quarter. On a full-year basis, ASML's revenue increased 16% from the previous fiscal year. Revenue for the quarter included the recognition of two High-NA systems, and bookings reached c13.2 billion - a level the company noted was 89% above consensus expectations of c7.0 billion.

Market observers also noted that BofA Securities maintained a Buy rating on ASML, with an unchanged price target of c1,454, signaling continued analyst confidence in the company's competitive position and growth prospects.

Taken together, the combination of record revenue, exceptionally strong bookings, and reiterated analyst support underscores robust demand for ASML's systems. At the same time, valuation metrics cited by third-party data services point to questions around the stock's premium relative to fair value, creating a countervailing consideration for investors.


Contextual note: The data points and analyst positions described here reflect reported company figures and public analyst ratings referenced above.

Risks

  • Valuation concern: A P/E of 53.19 and third-party data suggest the stock may be priced above its Fair Value, introducing valuation risk for investors.
  • Timing uncertainty: While bookings are unusually strong, the FY26 guidance and the expectation of sizable FY27 upgrades create uncertainty about the timing and pace at which orders will translate into revenue.
  • Analyst estimate sensitivity: Projected double-digit upgrades in 2027 and 2028 imply dependence on sustained demand and execution; failure to meet elevated expectations could pressure sentiment.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026